vs
BrightSpire Capital, Inc.（BRSP）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
BrightSpire Capital, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$83.2M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -0.4%），BrightSpire Capital, Inc.自由现金流更多（$55.1M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -6.8%）
该公司是英国大型投资信托，专注投资于商业服务、消费、教育与科技领域的中型市场企业，在伦敦证券交易所上市，是富时250指数的成份股。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
BRSP vs PBYI — 直观对比
营收规模更大
BRSP
是对方的1.1倍
$75.5M
营收增速更快
PBYI
高出28.1%
-0.4%
自由现金流更多
BRSP
多$40.7M
$14.4M
两年增速更快
PBYI
近两年复合增速
-6.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.2M | $75.5M |
| 净利润 | $-14.4M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | — | 22.7% |
| 净利率 | -17.3% | — |
| 营收同比 | -0.4% | 27.7% |
| 净利润同比 | 27.3% | — |
| 每股收益（稀释后） | $-0.11 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRSPPBYI
| Q4 25 | $83.2M | $75.5M | ||
| Q3 25 | $83.9M | $54.5M | ||
| Q2 25 | $85.9M | $52.4M | ||
| Q1 25 | $77.6M | $46.0M | ||
| Q4 24 | $83.5M | $59.1M | ||
| Q3 24 | $88.2M | $80.5M | ||
| Q2 24 | $91.4M | $47.1M | ||
| Q1 24 | $95.8M | $43.8M |
净利润BRSPPBYI
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $984.0K | $8.8M | ||
| Q2 25 | $-23.1M | $5.9M | ||
| Q1 25 | $5.3M | $3.0M | ||
| Q4 24 | $-19.7M | — | ||
| Q3 24 | $12.7M | $20.3M | ||
| Q2 24 | $-67.9M | $-4.5M | ||
| Q1 24 | $-57.1M | $-4.8M |
毛利率BRSPPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率BRSPPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | -1.7% | 17.6% | ||
| Q2 25 | -54.5% | 12.7% | ||
| Q1 25 | 5.1% | 8.7% | ||
| Q4 24 | -24.9% | 22.6% | ||
| Q3 24 | 13.2% | 27.4% | ||
| Q2 24 | -74.9% | -4.6% | ||
| Q1 24 | -59.4% | -5.3% |
净利率BRSPPBYI
| Q4 25 | -17.3% | — | ||
| Q3 25 | 1.2% | 16.2% | ||
| Q2 25 | -26.9% | 11.2% | ||
| Q1 25 | 6.9% | 6.5% | ||
| Q4 24 | -23.7% | — | ||
| Q3 24 | 14.4% | 25.2% | ||
| Q2 24 | -74.2% | -9.6% | ||
| Q1 24 | -59.6% | -11.0% |
每股收益（稀释后）BRSPPBYI
| Q4 25 | $-0.11 | $0.26 | ||
| Q3 25 | $0.00 | $0.17 | ||
| Q2 25 | $-0.19 | $0.12 | ||
| Q1 25 | $0.04 | $0.06 | ||
| Q4 24 | $-0.16 | $0.40 | ||
| Q3 24 | $0.09 | $0.41 | ||
| Q2 24 | $-0.53 | $-0.09 | ||
| Q1 24 | $-0.45 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.8M | $97.5M |
| 总债务越低越好 | $2.5B | $22.7M |
| 股东权益账面价值 | $938.4M | $130.3M |
| 总资产 | $3.6B | $216.3M |
| 负债/权益比越低杠杆越低 | 2.63× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资BRSPPBYI
| Q4 25 | $66.8M | $97.5M | ||
| Q3 25 | $113.4M | $94.4M | ||
| Q2 25 | $154.3M | $96.0M | ||
| Q1 25 | $200.9M | $93.2M | ||
| Q4 24 | $302.2M | $101.0M | ||
| Q3 24 | $263.8M | $96.7M | ||
| Q2 24 | $203.3M | $96.8M | ||
| Q1 24 | $221.5M | $107.2M |
总债务BRSPPBYI
| Q4 25 | $2.5B | $22.7M | ||
| Q3 25 | $2.2B | $34.0M | ||
| Q2 25 | $2.3B | $45.3M | ||
| Q1 25 | $2.3B | $56.7M | ||
| Q4 24 | $2.5B | $68.0M | ||
| Q3 24 | $2.6B | $79.3M | ||
| Q2 24 | $2.5B | $90.7M | ||
| Q1 24 | $2.6B | $102.0M |
股东权益BRSPPBYI
| Q4 25 | $938.4M | $130.3M | ||
| Q3 25 | $976.4M | $115.3M | ||
| Q2 25 | $994.4M | $104.7M | ||
| Q1 25 | $1.0B | $97.1M | ||
| Q4 24 | $1.0B | $92.1M | ||
| Q3 24 | $1.1B | $71.1M | ||
| Q2 24 | $1.1B | $48.5M | ||
| Q1 24 | $1.2B | $51.0M |
总资产BRSPPBYI
| Q4 25 | $3.6B | $216.3M | ||
| Q3 25 | $3.3B | $202.9M | ||
| Q2 25 | $3.4B | $194.9M | ||
| Q1 25 | $3.6B | $196.2M | ||
| Q4 24 | $3.7B | $213.3M | ||
| Q3 24 | $3.8B | $220.7M | ||
| Q2 24 | $3.8B | $205.0M | ||
| Q1 24 | $3.9B | $214.1M |
负债/权益比BRSPPBYI
| Q4 25 | 2.63× | 0.17× | ||
| Q3 25 | 2.22× | 0.30× | ||
| Q2 25 | 2.27× | 0.43× | ||
| Q1 25 | 2.27× | 0.58× | ||
| Q4 24 | 2.38× | 0.74× | ||
| Q3 24 | 2.36× | 1.12× | ||
| Q2 24 | 2.28× | 1.87× | ||
| Q1 24 | 2.17× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.0M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $55.1M | $14.4M |
| 自由现金流率自由现金流/营收 | 66.2% | 19.1% |
| 资本支出强度资本支出/营收 | 21.6% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $102.0M | $41.7M |
8季度趋势，按日历期对齐
经营现金流BRSPPBYI
| Q4 25 | $73.0M | $14.4M | ||
| Q3 25 | $29.9M | $9.7M | ||
| Q2 25 | $17.4M | $14.1M | ||
| Q1 25 | $10.5M | $3.6M | ||
| Q4 24 | $103.4M | $15.6M | ||
| Q3 24 | $31.3M | $11.0M | ||
| Q2 24 | $22.9M | $1.0M | ||
| Q1 24 | $24.6M | $11.2M |
自由现金流BRSPPBYI
| Q4 25 | $55.1M | $14.4M | ||
| Q3 25 | $27.4M | $9.7M | ||
| Q2 25 | $11.6M | $14.1M | ||
| Q1 25 | $8.0M | $3.6M | ||
| Q4 24 | $97.3M | $15.6M | ||
| Q3 24 | $28.3M | $11.0M | ||
| Q2 24 | $22.7M | $1.0M | ||
| Q1 24 | $22.2M | — |
自由现金流率BRSPPBYI
| Q4 25 | 66.2% | 19.1% | ||
| Q3 25 | 32.7% | 17.7% | ||
| Q2 25 | 13.4% | 26.8% | ||
| Q1 25 | 10.3% | 7.7% | ||
| Q4 24 | 116.6% | 26.4% | ||
| Q3 24 | 32.1% | 13.7% | ||
| Q2 24 | 24.9% | 2.1% | ||
| Q1 24 | 23.2% | — |
资本支出强度BRSPPBYI
| Q4 25 | 21.6% | 0.0% | ||
| Q3 25 | 2.9% | 0.0% | ||
| Q2 25 | 6.8% | 0.0% | ||
| Q1 25 | 3.2% | 0.1% | ||
| Q4 24 | 7.3% | 0.0% | ||
| Q3 24 | 3.4% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 2.5% | 0.0% |
现金转化率BRSPPBYI
| Q4 25 | — | — | ||
| Q3 25 | 30.36× | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 1.97× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.46× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
